

- Di, L., E. H. Kerns, S. Q. Li, and S. L. Petusky. 2006. High throughput microsomal stability assay for insoluble compounds. *International Journal of Pharmaceutics* 317: 54–60.
- Guo, S. and L. Huang. 2014. Nanoparticles containing insoluble drug for cancer therapy. *Biotechnology Advances* 32(4): 778–788.
- Hann, M. M. and T. I. Oprea. 2004. Pursuing the leadlikeness concept in pharmaceutical research. *Current Opinion in Chemical Biology* 8: 255–263.
- Hartmann, T., J. Schmitt, C. Röhring, D. Nimptsch, J. Noller, and C. Mohr. 2006. ADME related profiling in 96 and 384 well plate format—A novel and robust HT-assay for the determination of lipophilicity and serum albumin binding. *Current Drug Delivery* 3: 181–192.
- Kalepu, S. and V. Nekkanti. 2015. Insoluble drug delivery strategies: Review of recent advances and business prospects. *Acta Pharmaceutica Sinica B* 5(5): 442–453.
- Kerns, E. H. and L. Di. 2003. Pharmaceutical profiling in drug discovery. *Drug Discovery Today* 8: 316–323.
- Kola, I. and J. Landis. 2004. Can the pharmaceutical industry reduce attrition rates? *Nature Reviews Drug Discovery* 3: 711–715.
- Latify, L., S. Sohrabzhad, and M. Hadavi. 2017. Mesoporous silica as a support for poorly soluble drug: Influence of pH and amino group on the drug release. *Microporous and Mesoporous Materials* 250: 148–157.
- Lipinski, C. A. 2000. Drug-like properties and the causes of poor solubility and poor permeability. *Journal of Pharmaceutical and Toxicological Methods* 44: 235–249.
- Lipper, R. A. 1999. *E. pluribus* product. *Modern Drug Discovery* 2: 55–60.
- Liu, Z., J. T. Robinson, X. Sun, and H. Dai. 2008. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. *Journal of the American Chemical Society* 130(33): 10876–10877.
- McGilveray, I. J. 1996. Overview of workshop: In vitro dissolution of immediate release dosage forms: Development of in vivo relevance and quality control issues. *Drug Information Journal* 30: 1029–1037.
- Mitragotri, S., P. A. Burke, and R. Langer. 2014. Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies. *Nature Reviews Drug Discovery* 13(9): 655–672.
- Pace, S. N., G. W. Pace, I. Parikh, and A. K. Mishra. 1999. Novel injectable formulations of insoluble drugs. *Pharmaceutical Technology* 23: 116–134.
- Pepsin, X. J., T. R. Flanagan, D. J. Holt, A. Eidelman, D. Treacy, and C. E. Rowlings. 2016. Justification of drug product dissolution rate and drug substance particle size specifications based on absorption PBPK modeling for Lesinurad immediate release tablets. *Molecular Pharmaceutics* 13(9): 3256–3269.
- Porter, C. J. H. and W. N. Charman. 2001. In vitro assessment of oral lipid based formulations. *Advanced Drug Delivery Review* 50: S127–S147.
- Pouton, C. W. 1997. Formulation of self-emulsifying drug delivery systems. *Advanced Drug Delivery Reviews* 25: 47–58.
- Qiu, Y., Y. Chen, G. G. Zhang, L. Yu, and R. V. Mantri (Eds.). 2016. *Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice*. London, UK: Academic Press.
- Rodriguez-Aller, M., D. Guillaume, J. L. Veuthey, and R. Gurny. 2015. Strategies for formulating and delivering poorly water-soluble drugs. *Journal of Drug Delivery Science and Technology* 30: 342–351.
- Sarker, D. K. 2005. Engineering of nanoemulsions for drug delivery. *Cancer Drug Delivery* 2: 297–310.
- Shanker, R. M. 2005. Current concepts in the science of solid dispersion. *2nd Annual Simonelli Conference in Pharmaceutical Sciences*, June 9, Long Island University, Brookville, NY.
- Sweetana, S. and M. J. Akers. 1996. Solubility principles and practices for parenteral drug dosage from development. *PDA Journal of Pharmaceutical Science & Technology* 50: 330–342.
- Takagi, T., C. Ramachandran, M. Bermejo, S. Yamashita, L. X. Yu, and G. L. Amidon. 2006. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. *Molecular Pharmaceutics* 3(6): 631–643.
- Tanno, F., Y. Nishiyama, H. Kokubo, and S. Obara. 2004. Evaluation of hypromellose acetate succinate (HPMCAS) as a carrier in solid dispersions. *Drug Development and Industrial Pharmacy* 30: 9–17.
- Taylor, L. S. and G. G. Zhang. 2016. Physical chemistry of supersaturated solutions and implications for oral absorption. *Advanced Drug Delivery Reviews* 101: 122–142.
- Wasan, K. M. 2001. Formulation and physiological and biopharmaceutical issues in the development of oral lipid-based drug delivery systems. *Drug Development and Industrial Pharmacy* 27: 267–276.
- Willmann, S., W. Schmitt, J. Keldenich, J. Lipert, and J. B. Dressman. 2004. A physiological model for the estimation of the fraction dose absorbed in humans. *Journal of Medicinal Chemistry* 47: 4022–4031.
- Yamashita, S. and T. Furubayashi. 1998. In vitro–in vivo correlations: Application to water insoluble drugs. *Bulletin Technique Gattefossé* 91: 25–31.